Our data align with these findings, since we could hypothesize that in COVID-19 patients, carriers of SOD2*T genetic variant during SARS-CoV-2 infection with larger inflammatory damage to cardiomyocytes was present. The gene discussed is SOD2; the disease is COVID-19.